January 31, 2018 / 7:26 AM / 6 months ago

BRIEF-Kiadis Pharma Annoucnes Consistent Results From Single Dose 1-year With Prior Phase II Study

Jan 31 (Reuters) - KIADIS PHARMA NV:

* KIADIS PHARMA NV - LAST PATIENT DOSED WITH ATIR101™ IN PHASE II ‘008’ CLINICAL TRIAL

* KIADIS PHARMA NV - RESULTS FROM SINGLE DOSE 1-YEAR FOLLOW UP CONSISTENT WITH PRIOR PHASE II STUDY

* KIADIS PHARMA NV - DATA SUPPORTS ALREADY SUBMITTED MARKETING AUTHORIZATION APPLICATION

* KIADIS PHARMA NV - REMAINS ON TRACK TO POTENTIALLY OBTAIN (CONDITIONAL) EMA APPROVAL FOR ATIR101™ IN Q4 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below